Advertisement

Pathology & Oncology Research

, Volume 25, Issue 1, pp 437–438 | Cite as

Neutrophilia and the JAK2 V617F Mutation

  • Stephen E. Langabeer
  • Karl Haslam
Letter to the Editor
  • 38 Downloads

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405CrossRefGoogle Scholar
  2. 2.
    Langabeer SE (2012) Referral centre variation in requesting JAK2 V617F mutation analysis for the investigation of a myeloproliferative neoplasm. J Clin Pathol 65:1149–1150CrossRefGoogle Scholar
  3. 3.
    Gong JZ, Cook JR, Greiner RC et al (2013) Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report for the Association for Molecular Pathology. J Mol Diagn 15:733–744CrossRefGoogle Scholar
  4. 4.
    Weir AB, Lewis JB Jr, Arteta-Bulos R (2011) Chronic idiopathic neutrophilia: experience and recommendations. South Med J 104:499–504CrossRefGoogle Scholar
  5. 5.
    Ogunleye F, Ibrahim M, Allen E et al (2016) BCR-ABL testing by polymerase chain reaction in patients with neutrophilia: the William Beaumont Hospital experience and the case for rational laboratory tests request. J Oncol Pract 12:e1001–e1005Google Scholar
  6. 6.
    Tefferi A, Noel P, Hanson CA (2011) Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms. J Mol Diagn 13:461–466CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2017

Authors and Affiliations

  1. 1.Cancer Molecular Diagnostics, Central Pathology LaboratorySt. James’s HospitalDublinIreland

Personalised recommendations